| Project/Area Number |
22890085
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General internal medicine (including Psychosomatic medicine)
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
TAKANO Atsushi 滋賀医科大学, 医学部, 特任助教 (50582607)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
DAIGO Yataro 滋賀医科大学, 医学部, 特任教授 (30345029)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2011: ¥1,365,000 (Direct Cost: ¥1,050,000、Indirect Cost: ¥315,000)
Fiscal Year 2010: ¥1,495,000 (Direct Cost: ¥1,150,000、Indirect Cost: ¥345,000)
|
|---|
| Keywords | 肺がん / バイオマーカー / 癌 / トランスレーショナルリサーチ |
|---|
| Research Abstract |
Immunohistochemical analysis showed that LASEP3 was over-expressed in lung cancers. In addition, a high level of LASEP3 expression was associated with poor prognosis for NSCLC patients. The proportion of serum LASEP3-positive cases was 61. 8% of NSCLCs, while 5. 5% of healthy volunteers were falsely diagnosed. Furthermore, treatment of lung cancer cells with siRNAs against LASEP3 suppressed its expression and resulted in growth suppression of the lung cancer cells. We have identified LASEP3 as a potential target for the development of diagnostic and prognostic biomarkers for lung cancer.
|
